自从2014年在加拿大不列颠哥伦比亚省上市以来，依布替尼已经彻底改变了慢性淋巴细胞白血病（CLL）的治疗格局。我们分析了在2014年至2018年期间在不列颠哥伦比亚省接受第一线（1L，n=35）和复发/难治（R/R，n=335）CLL治疗的370名患者的治疗模式和现实生存结果。32％的患者频繁减少剂量和27％的患者频繁中断治疗。在中位随访时间为27.6个月的情况下，35％的患者停止了依布替尼治疗，主要是因为不良事件而不是疾病进展。在治疗过程中，87％的患者至少发生过一种不良事件。2年总生存率（OS）和无事件生存率（EFS）表现出色，分别为83.9％和76.1％，中位生存时间尚未达到。然而，停止依布替尼的患者从停药时间开始，中位OS仅为32.5个月，中位EFS仅为3.8个月，凸显了在现实世界中最小化毒性的必要性。

Ibrutinib has dramatically changed the treatment landscape for chronic lymphocytic leukemia (CLL) since its availability in British Columbia (BC), Canada in 2014. We analyzed patterns of use and real-world survival outcomes in 370 patients who received ibrutinib for first-line (1 L, n = 35) and relapsed/refractory (R/R, n = 335) CLL between 2014-2018 in BC. Dose reductions and interruptions were frequent in 32% and 27%, respectively. With a median follow-up of 27.6 months, 35% of patients discontinued ibrutinib, primarily for adverse events (AEs) rather than progressive disease. Over the course of treatment, 87% of patients experienced at least one adverse event. The 2-year overall survival (OS) and event-free survival (EFS) were excellent at 83.9% and 76.1%, respectively, with medians not reached. However, patients who discontinued ibrutinib had a median OS of 32.5 months and median EFS of only 3.8 months from time of discontinuation, highlighting the need to minimize toxicity in the real-world.